PLGA nanoparticles loaded with etoposide and quercetin dihydrate individually: In vitro cell line study to ensure advantage of combination therapy

Cancer Nanotechnology

Volumn 3, Issue 1-6, 2012, Pages 25-36

  Pimple, Smita ^a   Manjappa, Arehalli S ^a   Ukawala, Mukesh ^a   Murthy, R S R ^a,b  

^a M S UNIVERSITY OF BARODA   (India)

^b ISF COLLEGE OF PHARMACY   (India)

Author keywords

A549 cell line; Etoposide; Nanopreciptation technique; PLGA nanoparticles; Quercetin dihydrate

Indexed keywords

ETOPOSIDE; NANOPARTICLE; POLYGLACTIN; QUERCETIN; SURFACTANT;

ANALYTIC METHOD; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG POTENTIATION; DRUG SOLUBILITY; EPITHELIUM CELL; FREEZE DRYING; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ADENOCARCINOMA; NANOENCAPSULATION; NANOPRECIPITATION; PARTICLE SIZE; POLYMERIZATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

EID: 84870321542     PISSN: 18686958     EISSN: 18686966     Source Type: Journal    
DOI: 10.1007/s12645-012-0027-y     Document Type: Article

References (51)

1. Boik J (2001) Natural compounds in cancer therapy. Oregon Medical Press, Princeton Minnesota, pp 91-98, pp. 251-267.
2. Cierniak A, Kapiszewska M (2002) The effect of quercetin on DNA damage induced by etoposide. Polish J Environ Stud 11: 111-115.
3. Cierniak A, Papiez M, Kapiszewska M (2004) Modulatory effect of quercetin on DNA damage, induced by etoposide in bone marrow cells and on changes in the activity of antioxidant enzymes in rats. Proceedings Annales Academiae Medicae Bialostocensis 49(1): 167-169.
4. Corvazier E, Maclouf J (1985) Interference of some flavonoids and nonsteroidal anti-inflammatory drugs with oxidative metabolism of arachidonic acid by human platelets and neutrophils. Biochem Biophys Acta 835: 315-321.
5. Costa P, Lobo JMS (2001) Modeling and comparison of dissolution profiles. Eur J Pharm Sci 13: 123-133.
6. Debes A, Oerding M, Willers R, Göbel U, Wessalowski R (2003) Sensitization of human Ewing's tumor cells to chemotherapy and heat treatment by the bioflavonoid quercetin. Anticancer Res 23(4): 3359-3366.
7. Desai MP, Labhasetwar V, Amidon GL, Levy RJ (1996) Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 12: 1838-1845.
8. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400.
9. Folkman J (1971) Tumour angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
10. Fonseca C, Simões S, Gaspara R (2002) Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 83: 273-286.
11. Furness MS, Robinson TP, Ehlers T, Hubbard RB, Arbiser JL, Goldsmith DJ, Bowen JP (2005) Antiangiogenic agents: studies on fumagillin and curcumin analogs. Curr Pharm Des 11: 357-373.
12. Galindo-Rodriguez S, Allemann E, Fessi H, Doelker E (2004) Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion and nanoprecipitation methods. Pharm Res 21: 1428-1439.
13. Gasparini G, Longo R, Fanelli M, Teicher BA (2005) Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 23(6): 1295-1311.
14. Gõmez-Gaete C, Tsapis N, Besnard M, Bochot A, Fattal E (2007) Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int J Pharm 331: 153-159.
15. Hande KR (1998) Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34: 1514-1521.
16. Hande KR (2008) Topoisomerase II inhibitors. Updat Cancer Ther 3: 13-26.
17. Havesteen B (1983) Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol 32: 1141-1148.
18. Hoffman R, Graham L, Newlands ES (1989) Enhanced anti-proliferative action of busulphan by quercetin on the human leukaemia cell line K562. Br J Cancer 59: 347-348.
19. Hofmann J, Doppler W, Jakob A (1988) Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C. Int J Cancer 42: 382-388.
20. Hofmann J, Fiebig HH, Winterhalter BR (1990) Enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by quercetin. Int J Cancer 45: 536-539.
21. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
22. Igura K, Ohta T, Kuroda Y, Kaji K (2001) Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett 171: 11-16.
23. Jain RK, Willett CG, Boucher Y et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145-147.
24. Jasti BR, Du J, Vasavada RC (1995) Characterization of thermal behavior of etoposide. Int J Pharm 118: 161-167.
25. Kim KJ, Li B, Winer J, Li B, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844.
26. Kim SH, Yeo GS, Lim YS, Kang CD, Kim CM, Chung BS (1998) Suppression of multidrug resistance via inhibition of heat shock factor by quercetin in MDR cells. Exp Mol Med 30: 87-92.
27. Korsmeyer RW, Gurny R, Doelker EM, Buri P, Peppas NA (1983) Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 15: 25-35.
28. Kuhlman MK, Horsch E, Burkhardt G (1998) Reduction of cisplatin toxicity in cultured renal tubular cells by the bioflavonoid quercetin. Arch Toxicol 72: 536-540.
29. Levy J, Teuerstein I, Marbach M, Radian S, Sharoni Y (1984) Tyrosine protein kinase activity in the DMBA-induced rat mammary tumor: inhibition by quercetin. Biochem Biophys Res Commun 123: 1227-1233.
30. Ma ZS, Huynh TH, Ng CP et al (2004) Reduction of CWR22 prostate tumor xenograft growth by combined tamoxifen-quercetin treatment is associated with inhibition of angiogenesis and cellular proliferation. Int J Oncol 24: 1297-1304.
31. Mainardes RM, Evangelista RC (2005) PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm 290: 137-144.
32. Mohanraj VJ, Chen Y (2006) Nanoparticles: a review. Trop J Pharm Res 5(1): 561-573.
33. Mossmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
34. Mu L, Feng SS (2003) PLGA/TPGS nanoparticles for controlled release of paclitaxel: effect of emulsifier and drug loading ratio. Pharm Res 20(11): 1864-1872.
35. Painter FM (1998) Quercetin monograph. Altern Med Rev 3(2): 140-143.
36. Peppas NA (1985) Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 60: 110-111.
37. Peppas NA, Sahlin JJ (1989) A simple equation for the description of solute release. III. Coupling of diffusion and relaxation. Int J Pharm 57: 169-172.
38. Ramos S (2008) Review cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol Nutr Food Res 52: 507-526.
39. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell-lung cancer. N Engl J Med 355: 2542-2550.
40. Scambia G, Ranelletti FO, Panici PB (1992) Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum(II). Gynecol Oncol 45: 13-19.
41. Scambia G, Ranelletti FO, Panici PB, Piantelli M, Vincenzo R, Ferrandina G, Bonanno G, Capelli A, Mancuso S (1993) Quercetin induces type-II estrogen-binding sites in estrogen- receptor-negative (MDA-MB231) and estrogen-receptor-positive (MCF-7) human breast cancer cell lines. Int J Cancer 54: 462-466.
42. Scambia G, Ranelletti FO, Panici PB (1994) Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breastcancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 34: 459-464.
43. Sliutz G, Karlseder J, Tempfer C, Orel L, Holzer G, Simon MM (1996) Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy. Br J Cancer 74: 172-177.
44. Song X, Zhao Y, Hou S, Xu F, Zhao R, He J, Cai Z, Li Y, Chen Q (2008) Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur J Phar Biopharm 69: 445-453.
45. Spoerke D (2003) In: Rouse J (ed) AltMedDex® System. MicroMedex Inc., Englewood, Colorado.
46. Stolnik S, Illum L, Davis S (1995) Long circulating microparticulate drug carriers. Adv Drug Deliv Rev 16: 195-214.
47. Tabata Y, Ikada Y (1990) Phagocytosis of polymer microspheres by macrophages. Adv Polym Sci 94: 107-141.
48. Tan WF, Lin LP, Li MH et al (2003) Quercetin, a dietary-derived flavonoid, possesses antiangiogenic potential. Eur J Pharmacol 459: 255-262.
49. Xiao D, Zhu SP, Gu ZL (1998) Quercetin induced apoptosis in human leukemia HL-60 cell. Acta Pharmacol Sin 18: 280-283.
50. Yance DR, Sagar MS (2006) Targeting angiogenesis with integrative cancer therapies. Integr Cancer Ther 5(1): 9-29.
51. Yoshida M, Sakai T, Hosokawa N, Marui N, Matsumoto K, Fujioka A, Nishino H, Aoike A (1990) The effect of quercetin of cell cycle progression and growth of human gastric cancer cells. FEBS Lett 260: 10-13.